About GO Therapeutics
The generation of solid tumor targeting domains specific to cancer cells remains a significant challenge in the biopharmaceutical industry. GO Therapeutics’ targeting platforms and technologies hold the promise to unlock the full potential of antibody-drug conjugates, bi-specific T-cell engagers, and immune-based cell therapies.
GO Therapeutics is developing a range of cancer drug candidates that are exquisitely tumor specific.
We are developing antibodies against a novel class of tumor-specific glycoprotein antigens. These antigens are not found on healthy cells, making them ideal targets for bi-specific antibody T-cell engagement, CAR-T and ADC therapies. GO’s lead antibody development program is based on a bispecific antibody for T cell-redirection therapy.
- Focus : Manufacturer
- Industry : Biotechnology
